Exelixis Investor Relations Material
Latest events
Q4 2024
Exelixis
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Exelixis Inc
Access all reports
Exelixis, Inc., is a US-based biotechnology company within oncology. The company focuses on the discovery, development, and commercialization of new medicines to treat cancers in the U.S. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its products also comprise MINNEBRO tablets for the treatment of genetic conditions.
Key slides for Exelixis Inc
Q4 2024
Exelixis Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Exelixis Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
EXEL
Country
🇺🇸 United States